Status:

RECRUITING

Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care

Lead Sponsor:

Arkansas Children's Hospital Research Institute

Conditions:

Primary Ciliary Dyskinesia

Eligibility:

All Genders

2-99 years

Brief Summary

this study is aiming at learning more about primary ciliary dyskinesia (PCD) and tests that are used to diagnose this condition. One purpose of this study is to measure the level of nitric oxide in th...

Detailed Description

This will be an observational study. Participants who are referred by their clinician for nasal NO testing and meet the inclusion and exclusion criteria will be allowed to undergo testing. Informed co...

Eligibility Criteria

Inclusion

  • Individuals who are diagnosed with Primary Ciliary Dyskinesia OR
  • Individuals with abnormal PCD diagnostics (abnormal ciliary biopsy or PCD genetics) OR
  • Individuals with unexplained bronchiectasis OR
  • Individuals undergoing PCD diagnostic testing (ciliary biopsy, PCD genetic testing) or concern based on clinical symptoms (at least two of the following):
  • Neonatal respiratory distress
  • Organ laterality defects
  • Year-round cough starting in first year of life or bronchiectasis on chest CT
  • Year-round nasal congestion starting in first year of life or pansinusitis
  • Multiple ear infections in the first two years of life with sequelae (e.g. ear tubes, chronic effusion, abnormal audiological exam)
  • History of recurrent pneumonias (at least 2 in one year or more than 3 at any time)
  • Ability to provide consent for participation in study by the participants or guardian
  • Ability to perform the test
  • Age \>= 2 years of age

Exclusion

  • Individuals who are unable to understand the requirements of the study.
  • Individuals (or guardians) who are unwilling to provide consent.
  • Individuals who are unable to complete the testing
  • Recent history of sinus surgery (within four weeks) or bloody nose (within one week) of testing (they can be included at a later date)
  • Patients who are currently being treated (within one week) with antibiotics for sinusitis or respiratory symptoms (they can be included at a later date)
  • Age \<2 years of age

Key Trial Info

Start Date :

June 14 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2030

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT05287022

Start Date

June 14 2021

End Date

June 1 2030

Last Update

January 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Arkansas Children's Hospital

Little Rock, Arkansas, United States, 72202

Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care | DecenTrialz